Category: Include on Menu
-
Wall Street futures flat as investors weigh Anthropic growth against oil and economic risks: Dow Jones, S&P, Nasdaq
Wall Street is heading towards a muted start to the week, with U.S. equity futures indicating little change on Monday as investors balance softer economic data against persistent geopolitical and energy-market risks. Technology could be one area of strength following a Bloomberg report that Anthropic (NASDAQ:ANTP) has told prospective investors its second-quarter revenue increased by…
-
Bimergen Energy shares rise after Q2 revenue reaches $7.9 million
Bimergen Energy Corporation (AMEX:BESS) shares gained 3.01% in after-hours trading on Monday after the energy infrastructure developer reported second-quarter revenue of $7.9 million and adjusted earnings of $0.22 per share, supported by transactions involving battery energy storage projects. For the quarter ended June 30, 2026, Bimergen generated net income of $1.6 million and adjusted EBITDA…
-
Traws Pharma shares rise after Q2 loss comes in better than expected
Traws Pharma Inc. (NASDAQ:TRAW) shares gained 3.9% in pre-market trading on Monday after the clinical-stage biopharmaceutical company reported a second-quarter loss that was narrower than Wall Street had anticipated. For the quarter ended June 30, 2026, Traws posted an adjusted loss of $0.16 per share, comfortably beating the analyst consensus estimate for a loss of…
-
Jasper Therapeutics beats Q2 expectations but shares fall after results
Jasper Therapeutics Inc. (NASDAQ:JSPR) reported better-than-expected second-quarter 2026 results on Monday, although shares of the clinical-stage biotechnology company fell 4.24% in pre-market trading following the announcement. For the quarter ended June 30, 2026, Jasper recorded an adjusted loss of $0.10 per share, considerably better than the analyst consensus forecast for a loss of $0.28 per…
-
Accendra Health drops equity issuance plan as CEO succession process advances
Accendra Health (NYSE:ACH) has abandoned plans to establish an at-the-market equity issuance programme, citing recent market conditions, while also providing an updated timetable for appointing a successor to Chief Executive Christopher Pesicka. The proposed programme would have allowed Accendra to issue modest amounts of equity over time, with the proceeds intended to reduce debt. The…
-
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum
Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10.05% in pre-market trading on Monday after the company reported fiscal third-quarter results that fell well short of analyst expectations, despite signs of increasing institutional demand for LYMPHIR. Quarterly revenue came in at $1.5 million, substantially below the consensus estimate of $12.52 million. Revenue nevertheless improved from zero in…
-
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances
LeonaBio, Inc. (NASDAQ:LONA) reported a smaller-than-expected second-quarter loss on Monday as the clinical-stage biopharmaceutical company continued to advance its pivotal Phase 3 ELAINE-3 study of lasofoxifene. The company posted a loss of $0.80 per share for the quarter, outperforming analyst expectations for a loss of $1.12 per share. LeonaBio shares were unchanged in after-hours trading…
-
Trane Technologies and Eaton unveil integrated AI data centre design
Trane Technologies (NYSE:TT) and Eaton (NYSE:ETN) have launched a joint reference design that brings together thermal management and electrical infrastructure for the next generation of artificial intelligence data centres. The collaboration combines the companies’ respective cooling and power-management technologies into a coordinated architecture intended to support increasingly power-dense AI facilities. The medium-voltage design has been…
-
Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts
Vivos Therapeutics Inc. (NASDAQ:VVOS) shares fell 6.5% in pre-market trading on Monday after the medical device company reported second-quarter revenue below Wall Street expectations, despite delivering a smaller-than-anticipated adjusted loss. Revenue for the quarter reached $5.15 million, missing the analyst consensus estimate of $5.57 million. Adjusted loss per share came in at -$0.31, however, outperforming…
-
Union Pacific fuel surcharges exceed Q2 fuel costs by $91.1 million
Union Pacific (NYSE:UNP) collected $91.1 million more from fuel surcharges than it spent on fuel during the second quarter, according to a regulatory filing with the Surface Transportation Board first reported by Reuters. The surplus was substantially larger than those reported by rival rail operators and contributed directly to Union Pacific’s profitability. The figures are…